JP2018517434A - 筋関連障害及び生物学的プロセスのためのハイスループット且つ機能的なスクリーニング方法 - Google Patents
筋関連障害及び生物学的プロセスのためのハイスループット且つ機能的なスクリーニング方法 Download PDFInfo
- Publication number
- JP2018517434A JP2018517434A JP2018517479A JP2018517479A JP2018517434A JP 2018517434 A JP2018517434 A JP 2018517434A JP 2018517479 A JP2018517479 A JP 2018517479A JP 2018517479 A JP2018517479 A JP 2018517479A JP 2018517434 A JP2018517434 A JP 2018517434A
- Authority
- JP
- Japan
- Prior art keywords
- myotube
- muscle
- compound
- cell
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 68
- 210000003205 muscle Anatomy 0.000 title claims abstract description 44
- 238000012216 screening Methods 0.000 title description 17
- 230000031018 biological processes and functions Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 103
- 210000004027 cell Anatomy 0.000 claims abstract description 40
- 230000000694 effects Effects 0.000 claims abstract description 37
- 230000008602 contraction Effects 0.000 claims abstract description 20
- 230000004060 metabolic process Effects 0.000 claims abstract description 18
- 238000004113 cell culture Methods 0.000 claims abstract description 15
- 208000021642 Muscular disease Diseases 0.000 claims abstract description 13
- 238000000423 cell based assay Methods 0.000 claims abstract description 13
- 238000000338 in vitro Methods 0.000 claims abstract description 12
- 210000002363 skeletal muscle cell Anatomy 0.000 claims abstract description 12
- 201000009623 Myopathy Diseases 0.000 claims abstract description 11
- 230000004118 muscle contraction Effects 0.000 claims abstract description 10
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 238000013537 high throughput screening Methods 0.000 claims abstract description 4
- 230000033087 muscle system process Effects 0.000 claims abstract description 3
- 230000035778 pathophysiological process Effects 0.000 claims abstract description 3
- 210000003098 myoblast Anatomy 0.000 claims description 34
- 206010003694 Atrophy Diseases 0.000 claims description 25
- 230000037444 atrophy Effects 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 239000011575 calcium Substances 0.000 claims description 23
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 22
- 229910052791 calcium Inorganic materials 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 21
- 230000006698 induction Effects 0.000 claims description 16
- 238000004904 shortening Methods 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 230000004069 differentiation Effects 0.000 claims description 12
- 206010028289 Muscle atrophy Diseases 0.000 claims description 11
- 238000007876 drug discovery Methods 0.000 claims description 11
- 230000003278 mimic effect Effects 0.000 claims description 11
- 201000000585 muscular atrophy Diseases 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 10
- 206010020880 Hypertrophy Diseases 0.000 claims description 9
- 238000012239 gene modification Methods 0.000 claims description 9
- 230000005017 genetic modification Effects 0.000 claims description 9
- 235000013617 genetically modified food Nutrition 0.000 claims description 9
- 238000011534 incubation Methods 0.000 claims description 9
- 238000011002 quantification Methods 0.000 claims description 9
- 208000011683 Hereditary muscle disease Diseases 0.000 claims description 8
- 108090001108 Troponin T Proteins 0.000 claims description 8
- 102000004987 Troponin T Human genes 0.000 claims description 8
- 238000010191 image analysis Methods 0.000 claims description 8
- 230000035800 maturation Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 108010069091 Dystrophin Proteins 0.000 claims description 6
- 102000001039 Dystrophin Human genes 0.000 claims description 6
- 239000000090 biomarker Substances 0.000 claims description 6
- 230000004190 glucose uptake Effects 0.000 claims description 6
- 208000018360 neuromuscular disease Diseases 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 5
- 102000003945 NF-kappa B Human genes 0.000 claims description 5
- 108010057466 NF-kappa B Proteins 0.000 claims description 5
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 230000004807 localization Effects 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 230000020763 muscle atrophy Effects 0.000 claims description 5
- 102100025682 Dystroglycan 1 Human genes 0.000 claims description 4
- 108010071885 Dystroglycans Proteins 0.000 claims description 4
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 4
- 102000057208 Smad2 Human genes 0.000 claims description 4
- 238000004364 calculation method Methods 0.000 claims description 4
- 230000021164 cell adhesion Effects 0.000 claims description 4
- 238000012203 high throughput assay Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000002438 mitochondrial effect Effects 0.000 claims description 4
- 230000004660 morphological change Effects 0.000 claims description 4
- 108010084498 Myosin Heavy Chains Proteins 0.000 claims description 3
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims description 3
- 108010084272 syntrophin alpha1 Proteins 0.000 claims description 3
- 208000029578 Muscle disease Diseases 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 230000035987 intoxication Effects 0.000 claims description 2
- 231100000566 intoxication Toxicity 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 34
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 24
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 21
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 21
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 18
- 210000000715 neuromuscular junction Anatomy 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 12
- 229960004373 acetylcholine Drugs 0.000 description 12
- 230000007170 pathology Effects 0.000 description 11
- 208000010428 Muscle Weakness Diseases 0.000 description 10
- 206010028372 Muscular weakness Diseases 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 9
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 9
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 8
- 108010056852 Myostatin Proteins 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 201000006938 muscular dystrophy Diseases 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000004153 glucose metabolism Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000001076 sarcopenia Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010006895 Cachexia Diseases 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
- 102100021947 Survival motor neuron protein Human genes 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000002952 image-based readout Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 4
- 229940032712 succinylcholine Drugs 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 4
- 229960001844 tubocurarine Drugs 0.000 description 4
- 229960001722 verapamil Drugs 0.000 description 4
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002508 compound effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001114 myogenic effect Effects 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 102000016970 Follistatin Human genes 0.000 description 2
- 108010014612 Follistatin Proteins 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- 208000023137 Myotoxicity Diseases 0.000 description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000010399 Wasting Syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000009338 distal myopathy Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000003703 image analysis method Methods 0.000 description 2
- 238000003709 image segmentation Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229960001783 nicardipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150110188 30 gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- -1 IL1-β Chemical compound 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 229930001406 Ryanodine Natural products 0.000 description 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 1
- 102100027697 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Human genes 0.000 description 1
- 101710109122 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 101150113275 Smn gene Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 108010075653 Utrophin Proteins 0.000 description 1
- 102000011856 Utrophin Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000010120 metabolic dysregulation Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000302 myotoxic Toxicity 0.000 description 1
- 230000003630 myotoxic effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 1
- 238000002805 secondary assay Methods 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
(i)筋芽細胞又は筋管細胞の培養が可能な細胞培養デバイスを準備すること、
培養デバイスにおいて、細胞培養の空間的な制御を可能にする方法を用いて、健康な若しくは筋関連障害に罹患したヒトドナー若しくはヒトドナー群由来の筋芽細胞又は筋管細胞、又は筋障害を再現する初代細胞、細胞株、アイソジェニック細胞株若しくは分化幹細胞由来の筋芽細胞又は筋管細胞を付着させること、及び
空間的に制御された筋管培養を促進するように、細胞を所定のインキュベーション時間培養すること、である方法によって得たインビトロの筋管培養物を準備するステップと、
(ii)培養物に少なくとも1つの化合物を添加するステップと、
(iii)化合物とともに筋管を所定時間インキュベーションした後、筋管の構造的及び/又は機能的情報の読み取りを行って、筋管における化合物の効果を測定するステップと、
(iV)測定された効果に基づいて、健康な筋肉の特性を向上若しくは改変させる、又は筋障害を処置、レスキュー、若しくは治癒する化合物の能力を予測し、該特性又は該障害は、筋収縮、筋形態、又は筋代謝と関連するものであるステップとを含む。
硬質基材、及び
基材のヤング率が5kPa〜15kPaを含む軟質基材、から選択されるとよい。
骨格筋細胞の萎縮又は肥大に作用する治療用化合物を同定し、画像分析は、萎縮又は肥大特性について該化合物の効果を測定するために行われること、
骨格筋細胞の成熟に作用する治療用化合物を同定し、自動分析は、特定のバイオマーカー発現及び/又は局在化について該化合物の効果を測定するために行われること、
筋管収縮誘導を誘導又は阻害する治療用化合物を同定し、分析はカルシウム放出について該化合物の効果を測定するために行われること、
筋管収縮誘導を誘導又は阻害する治療用化合物を同定し、画像分析は筋管短縮及び/又は収縮について該化合物の効果を測定するために行われること、
骨格筋細胞の代謝に作用する治療用化合物を同定し、分析は、グルコース摂取、ミトコンドリア電位、及び/又は乳酸脱水素酵素の酵素活性について該化合物の効果を測定するために行われること、のために実施されることができる。
第1の実施形態では、本発明は、筋収縮障害に作用する薬剤の検出を可能にする細胞ベースのアッセイを用いて化合物をスクリーニングする方法を提供する。
第2の実施形態では、本発明は、筋管形態に作用する薬剤の検出を可能にする細胞ベースのアッセイを用いて化合物をスクリーニングする方法を提供する。
第3の実施形態では、本発明は、筋代謝障害に作用する薬剤の検出を可能にする細胞ベースのアッセイを用いて化合物をスクリーニングする方法を提供する。
[1] May2006 report to Congress on Implementation of the MD CARE Act, as submitted byDepartment of Health and Human Service's, National Institutes of Health.
[2]Lawler JM, (2011). Exacerbation of pathology by oxidative stress in respiratoryand locomotor muscles with Duchenne muscular dystrophy. J Physiol. 589(Pt9):2161-2170.
[3]Harisseh R, Chatelier A, Magaud C, Deliot N, Constantin B, (2013). Involvementof TRPV2 and SOCE in calcium influx disorder in DMD primary human myotubes witha specific contribution of α1-syntrophin and PLC/PKC in SOCE regulation. Am JPhysiol Cell Physiol.304(9):C881-894.
[4]Sharma U, Atri S, Sharma MC, Sarkar C, Jagannathan NR, (2003). Skeletal musclemetabolism in Duchenne muscular dystrophy (DMD): an in-vitro proton NMRspectroscopy study. Magn Reson Imaging. 21(2):145-153.
[5] HaJC, Richman DP, (2015). Myasthenia gravis and related disorders: Pathology andmolecular pathogenesis. Biochim Biophys Acta. 1852(4):651-657.
[6]Franssen FM, Wouters EF, Schols AM, (2002). The contribution of starvation,deconditioning and ageing to the observed alterations in peripheral skeletalmuscle in chronic organ diseases. Clin Nutr. 21:1-14.
[7]Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ, (2014). Cancer cachexia:understanding the molecular basis. Nat Rev Cancer. 14(11):754-762.
[8]Morley JE, Thomas DR, Wilson MM, (2006).Cachexia: pathophysiology and clinicalrelevance. Am J Clin Nutr. 83(4):735-743.
[9]Tomaszewski M, Stepien KM, Tomaszewska J, Czuczwar SJ, (2011). Statin-inducedmyopathies. Pharmacol Rep. 63(4):859-866.
[10]Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S, (2013). Muscle type andfiber type specificity in muscle wasting. Int J Biochem Cell Biol.45(10):2191-2199.
[11]Valdez G, Tapia JC, Lichtman JW, Fox MA, Sanes JR, (2012). Shared resistance toaging and ALS in neuromuscular junctions of specific muscles. PLoS One.7(4):e34640.
[12]Matsumoto T, Ikuta N, Mori M, Nagayama K, (2010). Mechanics of wrinkleformation: micromechanical analysis of skin deformation during wrinkleformation in ultraviolet-irradiated mice. Skin Res Technol. 16(2):179-89.
[13]Edens BM, Ajroud-Driss S, Ma L, Ma YC, (2015). Molecular mechanisms and animalmodels of spinal muscular atrophy. Biochim Biophys Acta.1852(4):685-692.
[14]McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S,Wilton SD, (2006). Induced dystrophin exon skipping in human muscle explants.Neuromuscul Disord. 16:583-590.
[15]Webster C, Blau HM, (1990). Accelerated age-related decline in replicativelife-span of Duchenne muscular dystrophy myoblasts: implications for cell andgene therapy. Somat Cell Mol Genet.16:557-565.
[16]Trendelenburg AU, Meyer A, Jacobi C, Feige JN, Glass DJ, (2012).TAK-1/p38/nNFκB signaling inhibits myoblast differentiation by increasinglevels of Activin A. Skelet Muscle. 2:3
[17]Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ, (2009).Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblastdifferentiation and myotube size. Am J Physiol Cell Physiol. 296:C1258-1270.
[18]Vandenburgh H, Shansky J, Benesch-Lee F, Barbata V, Reid J, Thorrez L,Valentini R, Crawford G, (2008). Drug-screening platform based on thecontractility of tissue-engineered muscle. Muscle Nerve. 37:438-447.
[19]Vandenburgh H, Shansky J, Benesch-Lee F, Skelly K, Spinazzola JM, Saponjian Y,Tseng BS, (2009). Automated drug screening with contractile muscle tissueengineered from dystrophic myoblasts. FASEB J. 23:3325-3334.
[20]Purslow PP, (2010). Muscle fascia and force transmission. J Bodyw Mov Ther.14:411-417.
[21]Ducreux S, Zorzato F, Muller C, Sewry C, Muntoni F, Quinlivan R, Restagno G,Girard T, Treves S, (2004). Effect of ryanodine receptor mutations oninterleukin-6 release and intracellular calcium homeostasis in human myotubesfrom malignant hyperthermia-susceptible individuals and patients affected bycentral core disease. J Biol Chem.15:43838-43846.
[22]Heunks LM, Machiels HA, Dekhuijzen PN, Prakash YS, Sieck GC, (2001). Nitricoxide affects sarcoplasmic calcium release in skeletal myotubes. J Appl Physiol.91:2117-2124.
[23]Nott MW. Drugs on skeletal muscle. Pharmacology. Vol II.
[24]Clausen T, Gissel H, (2005). Role of Na,K pumps in restoring contractilityfollowing loss of cell membrane integrity in rat skeletal muscle. Acta PhysiolScand. 183:263-271.
[25]Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ, (2014). Cancer cachexia:understanding the molecular basis. Nat Rev Cancer. 14(11):754-762.
[26]Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E, Minetti G, ZhaoP, Hoffman EP, Puri PL, Sartorelli V, (2004). Deacetylase inhibitors increasemuscle cell size by promoting myoblast recruitment and fusion through inductionof follistatin. Dev Cell. 6:673-684.
[27]Sakuma K, Yamaguchi A, (2012). Novel intriguing strategies attenuating tosarcopenia. J Aging Res. 2012:251217.
Claims (16)
- 筋生理学的プロセス及び筋病態生理学的プロセスに関連したアプリケーションパネルにおいて化合物の有効性を予測するために、骨格筋細胞の収縮、形態、及び代謝を評価する複数の自動細胞ベースアッセイを用いて、該化合物をハイスループットスクリーニングする方法であって、該方法は、
(i)筋芽細胞又は筋管細胞の培養が可能な細胞培養デバイスを準備すること、
前記培養デバイスにおいて、細胞培養の空間的な制御を可能にする方法を用いて、健康な若しくは筋関連障害に罹患したヒトドナー若しくはヒトドナー群由来の前記筋芽細胞若しくは筋管細胞、又は筋障害を再現する初代細胞、細胞株、アイソジェニック細胞株若しくは分化幹細胞由来の筋芽細胞若しくは筋管細胞を付着させること、及び
空間的に制御された筋管培養を促進するように、前記細胞を所定のインキュベーション時間培養すること、である方法によって得たインビトロの筋管培養物を準備するステップと、
(ii)前記培養物に少なくとも1つの化合物を添加するステップと、
(iii)前記化合物とともに前記筋管を所定時間インキュベーションした後、前記筋管の構造的及び/又は機能的情報の読み取りを行って、前記筋管における前記化合物の効果を測定するステップと、
(iV)測定された前記効果に基づいて、健康な筋肉の特性を向上若しくは改変させる、又は筋障害を処置、レスキュー、若しくは治癒する前記化合物の能力を予測し、前記特性又は前記障害は、筋収縮、筋形態、又は筋代謝と関連するものであるステップと、を含む方法。 - 筋消耗、筋不使用、又は遺伝性筋疾患を模倣するために、筋管の培養ステップにおいて、前記培養物に、少なくとも1つの筋萎縮誘導剤を添加すること、又は遺伝子改変を行うことをさらに含む、請求項1に記載の方法。
- 神経筋疾患、中毒、又は遺伝性筋疾患を模倣するために、筋管の培養ステップにおいて、前記培養物に、少なくとも1つの筋収縮阻害剤を添加すること、又は遺伝子改変を行うことさらに含む、請求項1に記載の方法。
- 代謝性疾患、又は遺伝性筋疾患を模倣するために、筋管の培養ステップにおいて、前記培養物に、少なくとも1つの筋代謝阻害剤を添加すること、又は遺伝子改変を行うことさらに含む、請求項1に記載の方法。
- 前記細胞培養の空間的な制御を可能にする方法はバイオプリンティングを含む、請求項1〜4のうちの1つに記載の方法。
- 前記細胞培養デバイスは、基材及び少なくとも1つの細胞接着パターンを含み、前記少なくとも1つの細胞接着パターンに、健康な若しくは代表的な筋障害に罹患したヒトドナー若しくはヒトドナー群由来の筋芽細胞、又は筋障害を再現する細胞株、アイソジェニック細胞株若しくは分化幹細胞由来の筋芽細胞を付着させ、前記筋芽細胞は、筋管への細胞分化を促進するように、分化培地で所定のインキュベーション時間培養される、請求項1〜5のうちの1つに記載の方法。
- 前記基材は、
硬質基材、及び
前記基材のヤング率が5kPa〜15kPaを含む軟質基材、から選択される、請求項6に記載の方法。 - 前記筋管の画像分析を行って、骨格筋細胞、特に筋管又は筋芽細胞の形態的変化を測定することをさらに含み、測定された前記形態的変化は、前記化合物とともにインキュベーションした後の前記筋管の面積及び最大幅を含み、画像分析は、筋管の画像2値化、前記筋管の距離マップの計算、及び前記距離マップからの各筋管の最大幅の計算を含む、請求項1〜7のうちの1つに記載の方法。
- 前記機能的情報の読み取りには、ミオシン重鎖、トロポニンT、ジストロフィン、α−シントロフィン、ジストログリカン、アセチルコリン受容体、Smad2/3、及び/又はNF−κBの発現及び局在化による、筋管成熟のバイオマーカーを含む、請求項1〜7のうちの1つに記載の方法。
- 前記機能的情報の読み取りには、ハイスループットアッセイにおける、前記筋管のはく離及び前記筋管の少なくとも1つの末端の折りたたみに相当するスポット数の定量化による、カルシウム放出及び結果としての筋管の短縮を含む、請求項1〜7のうちの1つに記載の方法。
- 前記機能的読み取りには、ハイスループットアッセイにおける、グルコース摂取、ミトコンドリア電位、及び/又は乳酸脱水素酵素の定量化による筋管代謝を含む、請求項1〜7のうちの1つに記載の方法。
- 創薬の分野において、骨格筋細胞の萎縮又は肥大に作用する治療用化合物を同定するための方法であって、前記画像分析が、萎縮特性又は肥大特性について前記化合物の効果を測定するために行われる、請求項8に記載の方法。
- 創薬の分野において、骨格筋細胞の成熟に作用する治療用化合物を同定するための方法であって、自動分析が、特定の前記バイオマーカーの発現及び/又は局在化について前記化合物の効果を測定するために行われる、請求項9に記載の方法。
- 創薬の分野において、筋管収縮誘導を誘導又は阻害する治療用化合物を同定するための方法であって、前記分析がカルシウム放出について前記化合物の効果を測定するために行われる、請求項10に記載の方法。
- 創薬の分野において、筋管収縮誘導を誘導又は阻害する治療用化合物を同定するための方法であって、前記画像分析が筋管短縮及び/又は収縮について前記化合物の効果を測定するために行われる、請求項10に記載の方法。
- 創薬の分野において、骨格筋細胞の代謝に作用する治療用化合物を同定するための方法であって、前記分析が、グルコース摂取、ミトコンドリア電位、及び/又は乳酸脱水素酵素の酵素活性について前記化合物の効果を測定するために行われる、請求項11に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305946.4 | 2015-06-18 | ||
EP15305946 | 2015-06-18 | ||
PCT/EP2016/063737 WO2016202850A1 (en) | 2015-06-18 | 2016-06-15 | High throughput and functional screening method for muscle related disorders and biological processes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018517434A true JP2018517434A (ja) | 2018-07-05 |
JP6905516B2 JP6905516B2 (ja) | 2021-07-21 |
Family
ID=53540699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018517479A Active JP6905516B2 (ja) | 2015-06-18 | 2016-06-15 | 筋関連障害及び生物学的プロセスのためのハイスループット且つ機能的なスクリーニング方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11061017B2 (ja) |
EP (1) | EP3311161B1 (ja) |
JP (1) | JP6905516B2 (ja) |
DK (1) | DK3311161T3 (ja) |
ES (1) | ES2874627T3 (ja) |
WO (1) | WO2016202850A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180372724A1 (en) * | 2017-06-26 | 2018-12-27 | The Regents Of The University Of California | Methods and apparatuses for prediction of mechanism of activity of compounds |
CN110956629B (zh) * | 2019-12-17 | 2023-04-07 | 中国科学院微小卫星创新研究院 | 一种肌管细胞形态学参数测量及提供其交互界面的方法 |
WO2023138792A1 (en) | 2022-01-24 | 2023-07-27 | Cytoo | Methods using trained classifier to distinguish between healthy and diseased myotubes |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080299086A1 (en) * | 2006-09-21 | 2008-12-04 | Tohoku University | Cultured muscle cells with high metabolic activity and method for production of the cultured muscle cells |
JP2010184879A (ja) * | 2009-02-10 | 2010-08-26 | Univ Of Tokyo | 抗筋萎縮剤 |
WO2011007866A1 (ja) * | 2009-07-16 | 2011-01-20 | 国立大学法人名古屋大学 | 筋強直性ジストロフィー治療薬 |
JP2015038100A (ja) * | 2008-07-23 | 2015-02-26 | ノバルティス アーゲー | スフィンゴシン一リン酸受容体調節因子および筋肉炎症を治療するためのその使用 |
WO2015091593A1 (en) * | 2013-12-18 | 2015-06-25 | Cytoo | Device and method for standardizing myoblast differentiation into myotubes |
-
2016
- 2016-06-15 WO PCT/EP2016/063737 patent/WO2016202850A1/en active Application Filing
- 2016-06-15 JP JP2018517479A patent/JP6905516B2/ja active Active
- 2016-06-15 ES ES16730348T patent/ES2874627T3/es active Active
- 2016-06-15 US US15/736,841 patent/US11061017B2/en active Active
- 2016-06-15 EP EP16730348.6A patent/EP3311161B1/en active Active
- 2016-06-15 DK DK16730348.6T patent/DK3311161T3/da active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080299086A1 (en) * | 2006-09-21 | 2008-12-04 | Tohoku University | Cultured muscle cells with high metabolic activity and method for production of the cultured muscle cells |
JP2015038100A (ja) * | 2008-07-23 | 2015-02-26 | ノバルティス アーゲー | スフィンゴシン一リン酸受容体調節因子および筋肉炎症を治療するためのその使用 |
JP2010184879A (ja) * | 2009-02-10 | 2010-08-26 | Univ Of Tokyo | 抗筋萎縮剤 |
WO2011007866A1 (ja) * | 2009-07-16 | 2011-01-20 | 国立大学法人名古屋大学 | 筋強直性ジストロフィー治療薬 |
WO2015091593A1 (en) * | 2013-12-18 | 2015-06-25 | Cytoo | Device and method for standardizing myoblast differentiation into myotubes |
Non-Patent Citations (1)
Title |
---|
INTEGR. BIOL. (CAMB)., vol. 2, no. 4, JPN6020013286, 2010, pages 193 - 201, ISSN: 0004442870 * |
Also Published As
Publication number | Publication date |
---|---|
JP6905516B2 (ja) | 2021-07-21 |
WO2016202850A1 (en) | 2016-12-22 |
EP3311161A1 (en) | 2018-04-25 |
ES2874627T3 (es) | 2021-11-05 |
DK3311161T3 (da) | 2021-06-14 |
EP3311161B1 (en) | 2021-04-21 |
US20180356400A1 (en) | 2018-12-13 |
US11061017B2 (en) | 2021-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Falk et al. | Modeling psychiatric disorders: from genomic findings to cellular phenotypes | |
Horsley et al. | Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent pathway | |
Meaburn et al. | Primary laminopathy fibroblasts display altered genome organization and apoptosis | |
Abrahamsen et al. | A patient-derived stem cell model of hereditary spastic paraplegia with SPAST mutations | |
EP2962698B1 (en) | Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to injury | |
J Tronstad et al. | Regulation and quantification of cellular mitochondrial morphology and content | |
McCusker et al. | Positional plasticity in regenerating Amybstoma mexicanum limbs is associated with cell proliferation and pathways of cellular differentiation | |
Simandi et al. | Arginine methyltransferase PRMT8 provides cellular stress tolerance in aging motoneurons | |
KR20190058620A (ko) | 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료 | |
JP6905516B2 (ja) | 筋関連障害及び生物学的プロセスのためのハイスループット且つ機能的なスクリーニング方法 | |
WO2019195800A1 (en) | Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells | |
Rowan et al. | Origin and function of the renal stroma in health and disease | |
US10093898B2 (en) | Purification of functional human astrocytes | |
Chang et al. | Sphingosine 1‐P hosphate Receptors Negatively Regulate Collagen Type I/III Expression in Human Bone Marrow‐derived Mesenchymal Stem Cell | |
JP6062371B2 (ja) | 神経変性疾患関連タンパク質の不溶性凝集体の製造方法 | |
Chen et al. | Microglial ERK signaling is a critical regulator of pro-inflammatory immune responses in Alzheimer’s disease | |
Schulpen et al. | Comparison of gene expression regulation in mouse-and human embryonic stem cell assays during neural differentiation and in response to valproic acid exposure | |
Thomas et al. | Rotator cuff tear state modulates self‐renewal and differentiation capacity of human skeletal muscle progenitor cells | |
US10254273B2 (en) | Method and kit for assessment of sodium channel-related anti- or pro-arrhythmic potential of compounds | |
US20220017870A1 (en) | Methods of identifying therapeutic targets for treating angiogenesis | |
US20240150710A1 (en) | Assembled three-dimensional cultures of human neurons and glia and their use | |
Alawadhi et al. | Model of how septin ring compartmentalization aids T-cell circumnavigation in extracellular matrices | |
Kim | Characterization of ReNCell for studying chromatin associated proteins MeCP2 and histone H1 | |
Shimshoni et al. | Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology | |
Berwanger et al. | Immortalised murine R349P desmin knock-in myotubes exhibit a reduced proton leak and decreased ADP/ATP translocase levels in purified mitochondria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180227 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180227 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190614 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200407 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200630 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200826 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200928 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210430 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210601 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210625 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6905516 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |